CSL · 15 hours ago
Senior Director, Early Partnerships & Transactions Lead
CSL is a global biotherapeutics leader focused on developing innovative therapies for patients. The Senior Director, Early Partnerships & Transactions Lead will drive early-stage deal-making and develop partnership strategies to enhance external innovation and create competitive advantages for the organization.
BiotechnologyHealth CareHealth DiagnosticsMedical
Responsibilities
Lead Early-Stage Deal-Making: Drive MTAs, research collaborations, options-to-license, and other innovative structures to accelerate external innovation
Source Strategic Assets: Partner with big pharma BD teams to identify and onboard deprioritized assets; maintain strong relationships with academia, biotech, and investors
Develop Partnership Strategy: Create onboarding advantages and transaction pathways that position the organization as a preferred partner
Align and Influence: Communicate deal vision and strategic rationale internally; collaborate with BD to amplify priorities to banks, VCs, and the investment community
Innovate Models: Design new partnership and funding approaches to expand deal-making capabilities
Ensure Governance & Performance for Early Partnerships: Set success metrics, monitor progress, and deliver value through disciplined execution
Qualification
Required
15+ years in biopharma business development, alliance management, or external innovation roles, with 10+ years in senior leadership positions
Demonstrated success in structuring and closing complex deals, including early-stage collaborations and creative funding models
Strong network within pharma BD organizations, biotech, and investment communities
Exceptional negotiation, relationship-building, and strategic thinking skills
Preferred
Advanced degree preferred (MBA, PhD, or equivalent)
Company
CSL
CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.
Funding
Current Stage
Public CompanyTotal Funding
$111M2013-12-20Acquired
2004-02-06Post Ipo Equity· $111M
1994-06-03IPO
Recent News
Pharma Letter
2026-01-03
2025-10-29
Company data provided by crunchbase